A Study of LAD603 in Adults With Alopecia Areata

Part of paid clinical trials in Omaha, Nebraska.

Sponsor
Almirall, S.A.
Study ID
NCT07311564
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LAD603 — DRUG
    LAD603 administered subcutaneously.
  • Placebo — OTHER
    LAD603 matching placebo administered subcutaneously.

Study Details

The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.

Key Dates

Start date
Dec 17, 2025
Status verified
Jan 2026
Primary completion
Jun 23, 2027
Completion
Nov 21, 2027

Study Design

Enrollment
136 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: LAD603 Dose A
    Participants will receive LAD603 Dose A , Subcutaneous (SC) injection from Day 1 up to 28 weeks.
  • Experimental: LAD603 Dose B
    Participants will receive LAD603 Dose B, SC injection from Day 1 up to 28 weeks.
  • Experimental: LAD603 Dose C
    Participants will receive LAD603 Dose C, SC injection from Day 1 up to 28 weeks.
  • Placebo Comparator: Placebo for LAD603
    Participants will receive Placebo for LAD603 SC injection from Day 1 up to 28 weeks.

Primary Outcome Measure

Percent Change from Baseline in the Severity of Alopecia Tool (SALT) Score [ Time Frame: Baseline, Week 28 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Investigator Site 1OmahaNebraska68144-

Find similar trials in Omaha, NE

By research site
Investigator· Omaha, NE

Related Studies